tidapaxicept

Tidapaxicept (IMM01) is a recombinant human SIRPα-IgG1 Fc fusion protein designed to target the CD47-SIRPα pathway. Developed by ImmuneOnco Biopharmaceuticals, it acts as a CD47 antagonist, blocking the "don't eat me" signal that tumor cells use to evade the immune system. By inhibiting the interaction between CD47 on cancer cells and SIRPα on macrophages, tidapaxicept promotes macrophage-mediated phagocytosis. A distinguishing feature of tidapaxicept is its engineered lack of binding to human erythrocytes, which minimizes the risk of hemagglutination and anemia, common toxicities associated with other CD47-targeting agents. It is currently being evaluated in Phase 3 clinical trials for PD-(L)1-refractory classical Hodgkin lymphoma and in Phase 2 trials for various other hematological malignancies and solid tumors.

Other names

tidapaxiceptSIRPα-Fc fusion protein